Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822731 | 0.90 | PIK3CA (0.63) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821609 | 0.89 | PIK3CA (0.66) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1822996 | 0.89 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1820136 | 0.87 | PIK3CA (0.52) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821881 | 0.86 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1821067 | 0.86 | PIK3CA (0.55) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1823920 | 0.86 | PIK3CA (0.51) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1827160 | 0.84 | PIK3CA (0.54) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL1819487 | 0.83 | PIK3CA (0.69) | PIK3CAPIK3CDPIK3CBPIK3CGROCK2 | |
| SCHEMBL6131796 | 0.82 | PIK3CA (0.71) | PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316831-B1 | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | NOVARTIS AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| EP-2316831-A1 | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | Novartis AG (CH) | 2011-05-04 | — | — | EP | disclosed |